PharmacoEconomics

, Volume 24, Issue 7, pp 661–672 | Cite as

Hepatitis C

Cost of Illness and Considerations for the Economic Evaluation of Antiviral Therapies
Review Article

Abstract

Chronic hepatitis C virus (HCV) infection affects 170 million individuals worldwide. As it is detected incidentally through the evaluation of liver function tests or at the time of blood donor testing, it is usually clinically silent until the advanced stages of liver disease have occurred, when treatment is less effective and shortages of donor liver organs limit the therapeutic options. Combination therapy with ribavirin and pegylated interferon has resulted in sustained viral negative response rates of 54–61%. Because treatment is expensive and not uniformly effective, and because not all chronically infected patients will develop complications, concerns have arisen regarding the cost effectiveness of combination therapy.

This paper reviews the public health and individual implications of HCV infections. Because of the latency of infection, numerous country-specific population analyses suggest that HCV will cause an increasing number of liver-related deaths over the next 10 years, despite the dramatic drop in incidence over the past 10–15 years. These deaths will be related to prevalent HCV infection from transfusion and injection drug use prior to identification of the virus and availability of screening tests in the late 1980s and early 1990s. HCV can reduce life expectancy and impair quality of life, yet not all patients will develop progressive liver disease, and antiviral treatment may have associated adverse effects.

Finally, to assess the value of antiviral drugs for HCV infection, this paper reviews studies examining the costs of antiviral drugs and of the disease itself along with response to antiviral therapy and the cost effectiveness of antiviral therapy. Although antiviral therapy appears to be expensive, when also considering the likelihood of sustained viral response to therapy, and the cost savings, quality-of-life improvement and prolongation of life expectancy from the prevention of HCV complications, antiviral treatment for HCV appears to be cost effective when compared with other well accepted medical interventions.

Notes

Acknowledgements

The author has received honoraria from the American Gastroenterological Association, Schering-Plough and Valeant and grants from the National Institute of Drug Abuse and Schering-Plough with regard to hepatitis C.

The author has no other conflicts of interest and has received no funding in the preparation of this review.

References

  1. 1.
    Consensus statement. EASL International Consensus Conference on hepatitis C; 1999 Feb 26–27; Paris. J Hepatol 1999; 31: 3-8Google Scholar
  2. 2.
    National Institutes of Health. Consensus development conference statement: management of hepatitis C — 2002. Hepatology 2002; 36: 53–20Google Scholar
  3. 3.
    Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis: the National Heart, Lung, and Blood Institute 5tudy Group. N Engl J Med 1992; 327: 1906–1911PubMedCrossRefGoogle Scholar
  4. 4.
    Tong MJ, El-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466PubMedCrossRefGoogle Scholar
  5. 5.
    Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26: 215–285CrossRefGoogle Scholar
  6. 6.
    Pagliaro L, Peri V, Linea C, et al. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol 1999; 31: 28–44PubMedGoogle Scholar
  7. 7.
    Freeman AI, Dare GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809–816PubMedCrossRefGoogle Scholar
  8. 8.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–832PubMedCrossRefGoogle Scholar
  9. 9.
    Alberti A, Noventa F, Benvegnu L, et al. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961–964PubMedGoogle Scholar
  10. 10.
    Hui CK, Belaye T, Montegrande K, et al. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003; 38: 511–517PubMedCrossRefGoogle Scholar
  11. 11.
    Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003; 52: 574–579PubMedCrossRefGoogle Scholar
  12. 12.
    Zarski JP, McHutchison J, Bronowicki JP, et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 2003; 38: 307–314PubMedCrossRefGoogle Scholar
  13. 13.
    Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97–104PubMedCrossRefGoogle Scholar
  14. 14.
    Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 451–455PubMedCrossRefGoogle Scholar
  15. 15.
    Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35–S46PubMedCrossRefGoogle Scholar
  16. 16.
    Seeff LB, Hollinger FE, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis: a National Heart, Lung, and Blood Institute Collaborative Study. Hepatology 2001; 33: 455–463PubMedCrossRefGoogle Scholar
  17. 17.
    Wong JB. Understanding the natural history of chronic hepatitis C: can decision analysis help? [abstract]. Hepatology 2000; 32 (Pt 2): 426ACrossRefGoogle Scholar
  18. 18.
    Kim WR, Benson J, Therneau T, et al. Why does fibrosis of hepatitis C progress faster in older patients? The role of competing risks [abstract]. Gastroenterology 2002; 122: A646CrossRefGoogle Scholar
  19. 19.
    Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777–782PubMedCrossRefGoogle Scholar
  20. 20.
    Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30–S34PubMedCrossRefGoogle Scholar
  21. 21.
    Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562–1569PubMedCrossRefGoogle Scholar
  22. 22.
    Deuffic D, Buffat L, Poynard T, et al. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596–1601PubMedCrossRefGoogle Scholar
  23. 23.
    Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol 2000; 14: 575–580PubMedGoogle Scholar
  24. 24.
    Hepatitis C Sub-Committee Australian Council on AIDS Hepatitis C and Related Diseases. Hepatitis C Virus Projections Working Group: estimates and projections of the hepatitis C virus epidemic in Australia 2002. Darlinghurst: The University of New South Wales, 2002: 1-40Google Scholar
  25. 25.
    Sagmeister M, Renner EL, Mullhaupt B, et al. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol 2002; 14: 25–34PubMedCrossRefGoogle Scholar
  26. 26.
    Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331–338PubMedCrossRefGoogle Scholar
  27. 27.
    Deuffic-Burban S, Wong JB, Valleron AJ, et al. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319–326PubMedCrossRefGoogle Scholar
  28. 28.
    Tanaka Y, Hanada K, Mizokami M, et al. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002; 99: 15584–15589PubMedCrossRefGoogle Scholar
  29. 29.
    El-Serag HE, Mason AC. Rising incidence of hepatocellular carcinoma. N Engl J Med 1999; 340: 745–750PubMedCrossRefGoogle Scholar
  30. 30.
    Wong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998; 280: 2088–2093PubMedCrossRefGoogle Scholar
  31. 31.
    Ware Jr JE, Bayliss MS, Mannocchia M, et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The International Hepatitis Interventional Therapy Group. Hepatology 1999; 30: 550–555PubMedCrossRefGoogle Scholar
  32. 32.
    Foster G. Hepatitis C virus: quality of life and side effects of treatment. J Hepatol 1999; 31: 2504CrossRefGoogle Scholar
  33. 33.
    Hassoun Z, Willems B, Deslauriers J, et al. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci 2002; 47: 2674–2681PubMedCrossRefGoogle Scholar
  34. 34.
    Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433–439PubMedCrossRefGoogle Scholar
  35. 35.
    Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440–446PubMedCrossRefGoogle Scholar
  36. 36.
    Fontana RJ, Hussain KB, Schwartz SM, et al. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 2002; 36: 401–407PubMedCrossRefGoogle Scholar
  37. 37.
    Manns MP, McHutchison JG, Gordon SC, et al. Pegintetferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 258: 958–965CrossRefGoogle Scholar
  38. 38.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982PubMedCrossRefGoogle Scholar
  39. 39.
    Koretz R. Interferon and hepatocellular carcinoma [letter]. Lancet 1996; 347: 194PubMedCrossRefGoogle Scholar
  40. 40.
    Harper S, Dienstag J. Can interferon alfa treatment prevent hepatocellular carcinoma in patients with chronic hepatitis C infection and compensated cirrhosis? Hepatology 1996; 23: 930–933PubMedCrossRefGoogle Scholar
  41. 41.
    Grimm I, Shaheen N. Can interferon prevent hepatocellular carcinoma in hepatitis C virus-induced cirrhosis? Gastroenterology 1996; 110: 2019–2021PubMedCrossRefGoogle Scholar
  42. 42.
    Poynard T, Opolon P. Hepatitis C: somber views of natural history and optimistic views of interferon treatment? [editorial]. Hepatology 1998; 27: 1443–1444PubMedCrossRefGoogle Scholar
  43. 43.
    Poynard T, Moussalli V, Ratziu V, et al. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Societe Royale BeIge de Gastro-enterologie. Acta Gastroenterol Belg 1998; 59: 431–437Google Scholar
  44. 44.
    Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875–881PubMedGoogle Scholar
  45. 45.
    Bonis PA, Ioannidis JP, Cappelleri JC, et al. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 1997; 26: 1035–1044PubMedCrossRefGoogle Scholar
  46. 46.
    Camma C, Giunta M, Linea C, et al. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26: 1187–1199PubMedCrossRefGoogle Scholar
  47. 47.
    Teramura K, Fukuda A, Kobayashi H, et al. Virus elimination and histologic improvement in patients with chronic hepatitis C treated with interferon alpha. J Clin Gastroenterol 1997; 25: 346–351PubMedCrossRefGoogle Scholar
  48. 48.
    Lau DT, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-alfa therapy for chronic hepatitis C. Hepatology 1998; 28: 1121–1127PubMedCrossRefGoogle Scholar
  49. 49.
    Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alia treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116: 378–386PubMedCrossRefGoogle Scholar
  50. 50.
    Reichard O, Glaumann H, Fryden A, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783–787PubMedCrossRefGoogle Scholar
  51. 51.
    Shindo M, Ken A, Olamo T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999; 85: 1943–1950PubMedGoogle Scholar
  52. 52.
    Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051–1055PubMedCrossRefGoogle Scholar
  53. 53.
    Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141–147PubMedCrossRefGoogle Scholar
  54. 54.
    Kuwana K, Ichida T, Kamimura T, et al. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J Gastroenterol Hepatol 1997; 12: 149–155PubMedCrossRefGoogle Scholar
  55. 55.
    Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94–99PubMedGoogle Scholar
  56. 56.
    Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394–1402PubMedCrossRefGoogle Scholar
  57. 57.
    Benvegnu L, Chemello L, Noventa F, et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83: 901–909PubMedCrossRefGoogle Scholar
  58. 58.
    Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124–1130PubMedCrossRefGoogle Scholar
  59. 59.
    Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435–1440PubMedCrossRefGoogle Scholar
  60. 60.
    Anonymous. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998; 351: 1535–1539CrossRefGoogle Scholar
  61. 61.
    Schalm SW, Fattovich G, Brouwer IT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997; 26: 128S–325PubMedCrossRefGoogle Scholar
  62. 62.
    Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687–1695PubMedCrossRefGoogle Scholar
  63. 63.
    Foster G, Goldin R, Thomas H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209–212PubMedCrossRefGoogle Scholar
  64. 64.
    Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy: the Consensus Interferon Study Group. Hepatology 1999; 29: 264–270PubMedCrossRefGoogle Scholar
  65. 65.
    Wright M, Forton D, Main J, et al. Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005; 12: 58–66PubMedCrossRefGoogle Scholar
  66. 66.
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174–181PubMedGoogle Scholar
  67. 67.
    Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105–114PubMedGoogle Scholar
  68. 68.
    Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36: S179–S184PubMedCrossRefGoogle Scholar
  69. 69.
    Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36: S161–S172PubMedCrossRefGoogle Scholar
  70. 70.
    Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: S152–S160PubMedCrossRefGoogle Scholar
  71. 71.
    Bain VG, Bonacini M, Govindarajan S, et al. A multicentre study of the usefulness of liver biopsy in hepatitis C. J Viral Hepat 2004; 11: 375–382PubMedCrossRefGoogle Scholar
  72. 72.
    Almasio PL, Niero M, Angioli D, et al. Experts’ opinions on the role of liver biopsy in HCV infection: a Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.). J Hepatol 2005; 43: 381–387PubMedCrossRefGoogle Scholar
  73. 73.
    Herrine SK, Friedman LS. Divining the role of liver biopsy in hepatitis C. J Hepatol 2005; 43: 374–376PubMedCrossRefGoogle Scholar
  74. 74.
    Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2000; 133: 665–675PubMedGoogle Scholar
  75. 75.
    Foster GR, Goldin RD, Main J, et al. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ 1997; 315: 453–458PubMedCrossRefGoogle Scholar
  76. 76.
    Levine R. Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time? Ann Intern Med 1998; 129: 323–326PubMedGoogle Scholar
  77. 77.
    Wong LL, McFall P, Wong LM. The cost of dying of end-stage liver disease. Arch Intern Med 1997; 157: 1429–1432PubMedCrossRefGoogle Scholar
  78. 78.
    Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866–874PubMedGoogle Scholar
  79. 79.
    Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318–1324PubMedCrossRefGoogle Scholar
  80. 80.
    Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425–432PubMedCrossRefGoogle Scholar
  81. 81.
    Wong JB, Davis GL, McHutchison JG, et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98: 2354–2362PubMedCrossRefGoogle Scholar
  82. 82.
    Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855–865PubMedGoogle Scholar
  83. 83.
    Shiell A, Briggs A, Farrell G. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis. Med J Aust 1994; 160: 268–272PubMedGoogle Scholar
  84. 84.
    Shiell A, Brown S, Farrell G. Hepatitis C: an economic evaluation of extended treatment with interferon. Med J Aust 1999; 171: 189–193PubMedGoogle Scholar
  85. 85.
    Anonymous. Interferon plus ribavirin for chronic hepatitis C. Med Lett Drugs Ther 1999; 41: 53–54Google Scholar
  86. 86.
    Inadomi JM, Sonnenberg A. Cost-effectiveness of initial combination therapy versus monotherapy followed by combination therapy in hepatitis C [abstract]. Gastroenterology 1999; 116: A316Google Scholar
  87. 87.
    Wong JB, Poynard T, Ling MH, et al. Cost-effectiveness of 24 or 48 weeks of interferon alfa-2b alone or with ribavirin as initial treatment of chronic hepatitis C: International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000; 95: 1524–1530PubMedGoogle Scholar
  88. 88.
    Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–652PubMedCrossRefGoogle Scholar
  89. 89.
    Grieve R, Roberts J, Wright M, et al. Cost-effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut. Epub 2006 Jan 24Google Scholar
  90. 90.
    Davis G, Beck J, Farrell G, et al. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. J Viral Hepat 1998; 5: 313–321PubMedCrossRefGoogle Scholar
  91. 91.
    Kim WR, Poterucha JJ, Dickson ER, et al. Optimal treatment strategy for chronic hepatitis C in 1999 [abstract]. Gastroenterology 1999; 116: A399Google Scholar
  92. 92.
    Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med 2000; 108: 366–373PubMedCrossRefGoogle Scholar
  93. 93.
    Sinha M, Das A. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000; 19: 23–30PubMedCrossRefGoogle Scholar
  94. 94.
    Sennfalt K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870–876PubMedCrossRefGoogle Scholar
  95. 95.
    Sagmeister M, Wong JB, Mullhaupt B, et al. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2001; 13: 483–488PubMedCrossRefGoogle Scholar
  96. 96.
    Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002; 50: 253–258PubMedCrossRefGoogle Scholar
  97. 97.
    Buti M, Casado MA, Fosbrook L, et al. Which is the most cost-effective combination therapy strategy using interferon alfa-2b plus ribavirin for naive patients with chronic hepatitis C? Clin Drug Invest 2002; 22: 31–39CrossRefGoogle Scholar
  98. 98.
    Grieve R, Roberts J. Economic evaluation for hepatitis C. Acta Gastroenterol Belg 2002; 65: 104–109PubMedGoogle Scholar
  99. 99.
    Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687–694PubMedCrossRefGoogle Scholar
  100. 100.
    Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228–237PubMedCrossRefGoogle Scholar
  101. 101.
    Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22: 257–265PubMedCrossRefGoogle Scholar
  102. 102.
    Sullivan SD, Jensen DM, Bernstein DE, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99: 1490–1496PubMedCrossRefGoogle Scholar
  103. 103.
    Shepherd J, Brodin HF, Cave CB, et al. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005; 21: 47–54PubMedCrossRefGoogle Scholar
  104. 104.
    Wong JB. Cost-effectiveness of treatments for chronic hepatitis C. Am J Med 1999; 107 (6B): 745–788Google Scholar
  105. 105.
    Davis G, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493–1499PubMedCrossRefGoogle Scholar
  106. 106.
    Malone DC, Tran IT, Poordad FF. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J Manag Care Pharm 2005; 11: 687–694PubMedGoogle Scholar
  107. 107.
    McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003; 7: 149–161PubMedCrossRefGoogle Scholar
  108. 108.
    Briefing materials for the Antivirals Advisory Committee on the safety and efficacy of PEGASYS® in combination with COPEGUSTM for the treatment of adult patients with chronic hepatitis C infection. FDA: Hoffman LaRoche, 2002 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3909BC02FDA%20briefing%2Opackage%20.pdf [Accessed 2006 Jun 13]Google Scholar
  109. 109.
    US Food and Drug Administration. Treatment response by geographic location: peginterferon alfa-2b/RBV [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/02/slides/39090PH1_0l_Murphy/sld007.htm [Accessed 2006 Jun 13]Google Scholar
  110. 110.
    Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36: S145–s151PubMedCrossRefGoogle Scholar
  111. 111.
    Weinstein M. High-priced technology can be good value for money. Ann Intern Med 1999; 130: 857–858PubMedGoogle Scholar
  112. 112.
    Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824–831PubMedCrossRefGoogle Scholar
  113. 113.
    Liang T. Combination therapy for hepatitis C infection. N Engl J Med 1998; 339: 1549–1550PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Division of Clinical Decision Making, Department of MedicineTufts University School of Medicine, Tufts-New England Medical Center, Tupper Research InstituteBostonUSA

Personalised recommendations